Document Detail

Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty.
MedLine Citation:
PMID:  15522928     Owner:  NLM     Status:  MEDLINE    
Familial male-limited precocious puberty is a rare cause of precocious puberty due to activating mutations of the LH receptor, leading to early onset virilization and short stature. Two therapeutic approaches have been proposed: the P450 cytochrome inhibitor ketoconazole or combined treatment with spironolactone and testolactone. Results on adult heights have not been reported to date after these two treatments, and in this study we present results from five patients treated with ketoconazole at a median dose of 16.2 mg/kg.d for a median of 6.2 yr. Adult height was 173 cm (median; interquartile range, 14), similar to target height (175 cm; interquartile range, 9) and significantly higher than pretreatment predicted height (165 cm; interquartile range, 12; P < 0.01). During treatment, 39 of 58 (68%) testosterone measurements were less than 0.5 ng/ml (1.7 nmol/liter), nine of 58 (15%) were between 0.5 and 1 ng/ml (3.5 nmol/liter), and 10 of 58 (17%) were above 1 ng/ml. We observed a physiological increase in GnRH-stimulated LH levels after the age of 10 yr, and none of the patients had early activation of the gonadotropic axis. Liver tolerance was excellent, and only one patient had a transient and modest increase in serum transaminases. We conclude that ketoconazole is an efficient and well tolerated long-term treatment of familial male-limited precocious puberty that should be proposed as a first line therapy.
Leandro Soriano-Guillén; Najiba Lahlou; Geneviève Chauvet; Marc Roger; Jean Louis Chaussain; Jean Claude Carel
Related Documents :
20190538 - Can the tw3 bone age determination method provide additional criteria for growth hormon...
7880778 - Percutaneous alcohol sclerotherapy of simple hepatic cysts. results from a multicentre ...
23078738 - Open versus endovascular stent graft repair of abdominal aortic aneurysms: a meta-analy...
20080848 - Delayed remission after transsphenoidal surgery in patients with cushing's disease.
8657908 - Severe ascites: efficacy of the transjugular intrahepatic portosystemic shunt in treatm...
8975988 - Effects of cisapride on abnormally prolonged endogastric alkalinity time and delayed ga...
Publication Detail:
Type:  Journal Article     Date:  2004-11-02
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  90     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-01-11     Completed Date:  2005-02-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  147-51     Citation Subset:  AIM; IM    
Department of Pediatric Endocrinology and Institut National de la Santé et de la Recherche Médicale, U561, Groupe Hospitalier Cochin-Saint Vincent de Paul, Faculté Cochin, Université Paris V, 82 avenue Denfert Rochereau, 75014 Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Determination by Skeleton
Body Height*
Child, Preschool
Follow-Up Studies
Ketoconazole / therapeutic use*
Luteinizing Hormone / blood
Puberty, Precocious / drug therapy*,  genetics,  physiopathology
Reg. No./Substance:
65277-42-1/Ketoconazole; 9002-67-9/Luteinizing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk fact...
Next Document:  Gonadotroph tumor associated with multiple endocrine neoplasia type 1.